Relationship between serum uric acid level and liver fat content in
newly diagnosed type 2 diabetic mellitus patients

doi:10.3760/cma.j.issn.1007-1245.2022.05.016

Abstract

Abstract: Objective　To investigate the relationship between serum uric acid level and liver fat content in newly diagnosed type 2 diabetic mellitus (T2DM) patients. Methods　A total of 195 patients with newly diagnosed T2DM who were hospitalized in Department of Endocrinology, Xiaogan Hospital Affiliated to Wuhan University of Science and Technology from January 2019 to June 2021 were selected. The hepatic controlled attenuation parameter (CAP) was measured by the FibroScan® system. The standard oral glucose tolerance test (OGTT) and insulin release test (IRT) were carried out. The patients' essential information, blood routine, blood biochemistry, four indicators of hepatic fibrosis, and glycosylated hemoglobin (HbA1c) were collected. The early phase insulin secretion index (ΔI30/ΔG30), islet β-cell function index (HOMA-β), and insulin resistance index (HOMA-IR) were calculated. The blood glucose peak (Gmax) and insulin secretion peak (Imax) after glucose load were obtained by the polynomial function curve fitting method. We divided all the subjects into a low CAP group (CAP≤197.7 db/m; 67 cases), a middle CAP group (197.7 db/m <CAP≤216.6 db/m; 64 cases), and a high CAP group (CAP＞216.6 db/m; 64 cases) based on the hepatic CAP tertiles. The clinical parameters were firstly compared between the groups. The correlations of liver CAP with other indicators were analyzed. The influencing factors of liver CAP were estimated. One-way ANOVA, Kruskal-Wallis H test, and χ² test were applied. Results　There were statistical differences in hyperuricemia, body mass index (BMI), fasting insulin level (I0), I30 (insulin level 30 minutes after 75 g OGTT), I60, I120, I180, Imax, HOMA-β, HOMA-IR, type IV collagen (IV-Col), a anine amino-transferase(ALT), alkaline phosphatase (ALP), gamma-glutamyl transpeptidase (GGT), and blood urea nitrogen BUN between the three groups (all P<0.05). The high CAP group had higher hyperuricemia and BMI than the other groups (all P<0.05). The high CAP group had higher I0, I30, I60, I120, Imax, HOMA-β, HOMA-IR, and GGT but lower BUN than the low CAP group (all P<0.05). The low CAP group had lower I180, IV-Col, and ALP than the other groups (all P<0.05). The CAP was positively correlated with BMI, I0, I30, I60, I120, I180, Imax, HOMA-β, HOMA-IR, IV-Col, ALT, ALP, and GGT (all P<0.05). Multivariate logistic regression analysis revealed that hyperuricemia [OR=2.380, 95%CI (1.023,5.538)] and obese (BMI≥28.0 kg/m²) [OR=3.901, 95%CI (1.491, 10.207)] were protective factors for CAP(both P<0.05). Conclusion　The elevated serum uric acid level and obesity (BMI≥28.0 kg/m²) are risk factors for increase of liver fat content in newly diagnosed type 2 diabetic mellitus patients.

Key words: Serum uric acid, Type 2 diabetes mellitus, Liver fat content, Body mass index, Obesity

摘要： 目的　探讨血清尿酸水平与初诊2型糖尿病（type 2 diabetic mellitus，T2DM）患者肝脏脂肪含量的相关性。方法　选取2019年1月至2021年6月于武汉科技大学附属孝感医院住院的初诊T2DM患者195例，均通过FibroScan测量肝脏受控衰减参数（controlled attenuation parameter，CAP），并行口服糖耐量试验（oral glucose tolerance test，OGTT）及胰岛素释放试验（insulin release test，IRT）。收集患者的基本信息、血常规、生化、肝纤四项及糖化血红蛋白（HbA1c）；计算早相胰岛素分泌指数（ΔI30/ΔG30）、胰岛β细胞功能指数（HOMA-β）、胰岛素抵抗指数（HOMA-IR）。根据多项式拟合法获得OGTT糖负荷后血糖峰值（Gmax）及胰岛素分泌峰值（Imax）。根据肝脏脂肪含量（以CAP值表示）三分位数将研究对象分为低CAP组［CAP≤197.7 db/m，共67例，年龄（54±11）岁，其中男53例］、中CAP组［197.7 db/m<CAP≤216.6 db/m，共64例，年龄（53±9）岁，其中男42例］和高CAP组［CAP>216.6 db/m，共64例，年龄（54±11）岁，其中男40例］。比较各组的临床参数，探讨肝脏CAP值与其他指标的相关性，筛选肝脏CAP值的影响因素。采用单因素方差分析、Kruskal-Wallis H检验、χ²检验等。结果　3组患者高尿酸血症、体质量指数（BMI）、空腹胰岛素（I0）、I30（75 g葡萄糖负荷后30 min胰岛素）、I60、I120、I180、Imax、HOMA-β、HOMA-IR、Ⅳ型胶原、谷丙转氨酶、碱性磷酸酶、γ-谷氨酰转肽酶及血尿素氮水平比较，差异均有统计学意义（均P<0.05）；其中高CAP组高尿酸血症、BMI水平高于低CAP组和中CAP组（均P<0.05）；高CAP组I0、I30、I60、I120、Imax、HOMA-β、HOMA-IR、γ-谷氨酰转肽酶水平高于低CAP组，血尿素氮水平低于低CAP组（均P<0.05）；低CAP组I180、Ⅳ型胶原、碱性磷酸酶水平低于中CAP组和高CAP组（均P<0.05）。肝脏CAP值与BMI、I0、I30、I60、I120、I180、Imax、HOMA-β、HOMA-IR、Ⅳ型胶原、谷丙转氨酶、碱性磷酸酶、γ-谷氨酰转肽酶呈正相关（均P<0.05）。多元logistic回归分析显示，高尿酸血症［OR=2.380，95%CI（1.023，5.538）］和肥胖（BMI≥28.0 kg/m²）［OR=3.901，95%CI（1.491，10.207）］是CAP值的保护因素（均P<0.05）。结论　血清尿酸水平升高和肥胖（BMI≥28.0 kg/m²）是初诊T2DM患者肝脏脂肪含量增加的危险因素。

关键词: 血清尿酸, 2型糖尿病, 肝脏脂肪含量, 体质量指数, 肥胖

Liao Shibo, Wu Min, Zou Yi, Yan Yimin, Huang Shuyu, Zhu Zhao, Huang Gao, Li Ling. Relationship between serum uric acid level and liver fat content in newly diagnosed type 2 diabetic mellitus patients[J]. International Medicine and Health Guidance News, 2022, 28(5): 662-668.

廖世波, 吴敏, 邹毅, 晏益民, 黄淑玉, 朱钊, 黄高, 李玲. 血清尿酸水平与初诊2型糖尿病患者肝脏脂肪含量的相关性研究[J]. 国际医药卫生导报, 2022, 28(5): 662-668.

References

[1] Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes[J]. Hepatology, 2016,64(1):73-84. DOI: 10.1002/hep.28431.

[2] Zhou F, Zhou J, Wang W, et al. Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018: a systematic review and meta-analysis[J]. Hepatology, 2019, 70(4): 1119-1133. DOI: 10.1002/hep.30702.

[3] Dai W, Ye L, Liu A, et al. Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a meta-analysis[J]. Medicine, 2017, 96(39): e8179. DOI: 10.1097/MD.0000000000008179.

[4] 张林杉,卞华,颜红梅,等.2型糖尿病患者肝脏脂肪含量与肝病结局的相关性研究[J].中华内分泌代谢杂志,2014,30(1):3-7.DOI:10.3760/cma.j.issn.1000-6699.2014.01.002.

[5] European Association for Study of Liver, Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: non-invasive tests for evaluation of liver disease severity and prognosis[J]. J Hepatol, 2015,63(1):237-264. DOI: 10.1016/j.jhep.2015. 04.006.

[6] Lim JK, Flamm SL, Singh S, et al. American gastroenterological association institute guideline on the role of elastography in the evaluation of liver fibrosis[J]. Gastroenterology, 2017,152(6):1536-1543. DOI: 10.1053/j.gastro.2017.03.017.

[7] World Health Orgnization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia:report of a WHO/IDF consultation,2006[M].Geneva:WHO Document Production Services,2006.

[8] Eslam M, Sanyal AJ, George J, et al. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease[J]. Gastroenterology, 2020,158(7):1999-2014.e1. DOI: 10.1053/j.gastro.2019.11.312.

[9] Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement[J]. J Hepatol, 2020,73(1):202-209. DOI: 10.1016/j.jhep.2020.03.039.

[10] Bril F, Cusi K. Nonalcoholic fatty liver disease: the new complication of type 2 diabetes mellitus[J]. Endocrinol Metab Clin North Am, 2016,45(4):765-781. DOI: 10.1016/j.ecl.2016.06.005.

[11] Taylor R, Barnes AC. Can type 2 diabetes be reversed and how can this best be achieved? James Lind Alliance research priority number one[J]. Diabet Med, 2019,36(3):308-315. DOI: 10.1111/dme.13851.

[12] Taylor R, Al-Mrabeh A, Sattar N. Understanding the mechanisms of reversal of type 2 diabetes[J]. Lancet Diabetes Endocrinol, 2019,7(9):726-736. DOI: 10.1016/S2213-8587(19)30076-2.

[13] Kwok R, Choi KC, Wong GL, et al. Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study[J]. Gut, 2016,65(8):1359-1368. DOI: 10.1136/gutjnl-2015-309265.

[14] Wang T, Lu J, Shi L, et al. Association of insulin resistance and β-cell dysfunction with incident diabetes among adults in China: a nationwide, population-based, prospective cohort study[J]. Lancet Diabetes Endocrinol, 2020,8(2):115-124. DOI: 10.1016/S2213-8587(19)30425-5.

[15] 赵雪诚,万政策,李冰丽,等.体检人群中高尿酸血症与脂肪肝的相关性研究[J].中西医结合肝病杂志,2020,30(4):320-322.DOI:10.3969/j.issn.1005-0264.2020.04.010.

[16] Lin H, Li Q, Liu X, et al. Liver fat content is associated with elevated serum uric acid in the chinese middle-aged and elderly populations: Shanghai changfeng study[J]. PLoS One, 2015, 10(10): e0140379. DOI: 10.1371/journal.pone. 0140379.

[17] Wang J, Ma L, Chen S, et al. Risk for the development of non-alcoholic fatty liver disease: a prospective study[J]. J Gastroenterol Hepatol, 2018,33(8):1518-1523. DOI: 10.1111/jgh.14105.

[18] Li C, Hsieh MC, Chang SJ. Metabolic syndrome, diabetes, and hyperuricemia[J]. Curr Opin Rheumatol, 2013,25(2):210-216. DOI: 10.1097/BOR.0b013e32835d951e.

[19] Zhu Y, Hu Y, Huang T, et al. High uric acid directly inhibits insulin signalling and induces insulin resistance[J]. Biochem Biophys Res Commun, 2014,447(4):707-714. DOI: 10.1016/j.bbrc.2014.04.080.

[20] Choi YJ, Shin HS, Choi HS, et al. Uric acid induces fat accumulation via generation of endoplasmic reticulum stress and SREBP-1c activation in hepatocytes[J]. Lab Invest, 2014,94(10):1114-1125. DOI: 10.1038/labinvest.2014.98.

[21] Wan X, Xu C, Lin Y, et al. Uric acid regulates hepatic steatosis and insulin resistance through the NLRP3 inflammasome-dependent mechanism[J]. J Hepatol, 2016,64(4):925-932. DOI: 10.1016/j.jhep.2015.11.022.

[22] 杨虹,杨小红,青玉凤,等.固有免疫和适应性免疫在痛风性关节炎发病机制中的研究进展[J].中华风湿病学杂志,2016,20(6):415-417.DOI:10.3760/cma.j.issn.1007-7480.2016.06.015.

[23] Klisic A, Isakovic A, Kocic G, et al. Relationship between oxidative stress, inflammation and dyslipidemia with fatty liver index in patients with type 2 diabetes mellitus[J]. Exp Clin Endocrinol Diabetes, 2018,126(6):371-378. DOI: 10.1055/s-0043-118667.

Relationship between serum uric acid level and liver fat content in newly diagnosed type 2 diabetic mellitus patients

血清尿酸水平与初诊2型糖尿病患者肝脏脂肪含量的相关性研究

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 2

Recommended Articles

Metrics

[1]	Zhang Huaqin, Zheng Yanwen, Wu Haiyan. Mechanism of obesity influencing thyroid function in patients with obstructive sleep apnea hypopnea syndrome [J]. International Medicine and Health Guidance News, 2022, 28(1): 75-78.
[2]	Wu Min, Huang Shuyu, Wang Xing, Zou Yi, Hu Xiaoping, Jiang Jingwen, Liao Shibo, Zhu Zhao, Huang Gao, Li Ling. Correlation of zinc-a2-glycoprotein with C-peptide and uric acid in patients type 2 diabetes mellitus [J]. International Medicine and Health Guidance News, 2022, 28(1): 79-81.